Genetic deep dive uncovers hidden clues in rare bone disease
NCT ID NCT05062629
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at 29 people with hypophosphatasia, a rare bone disease, who had no known genetic cause from standard tests. Researchers used whole genome sequencing to find hidden genetic changes in the ALPL gene. The goal was to better understand the disease and improve genetic diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors identify genetic causes of hypophosphatasia that standard tests miss, leading to better diagnosis.
- What could go wrong
- This is an observational study with only 29 participants, so findings may not apply to everyone. It does not test any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Newborn screening study aims to catch rare diseases at birth
- Scientists launch largest-ever natural history study for rare bone disease hypophosphatasia
- Could your body fight back against this rare disease drug?
- New study tracks rare bone disease to unlock clues for better diagnosis
- Withdrawn study aimed to counteract antibodies blocking hypophosphatasia drug
- New study aims to cut diagnostic delays for rare bone disease